Mutations at BTK C481 are the most common mutations seen in pooled trial data of chronic lymphocytic leukemia (CLL) patients on ibrutinib, leading to resistance and progressive disease (PD).
My last three doses of full-strength epcoritamab (48 mg) have been nonevents. There was some mild fatigue and itching the next day, but there is really nada to report. No cytokine release syndrome (CRS), for sure. All good.
Five years after completing venetoclax – obinutuzumab to treat chronic lymphocytic leukemia (CLL), over half of the treatment-naive patients remained in remission, and over 60% did not require second-line treatment, including many high-risk patients.
Acalabrutinib and zanubrutinib have similar excellent efficacy in relapsed or refractory chronic lymphocytic leukemia (CLL).
There is no excerpt because this is a protected post.
No new concerns or safety signals were found in old and frail chronic lymphocytic leukemia (CLL) patients treated with acalabrutinib.
Overall response rate (ORR) is a robust surrogate marker for progression-free survival (PFS), especially when chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) is treated with a Bruton tyrosine kinase inhibitor (BTKi) such as ibrutinib, acalabrutinib or zanubrutinib, but is not well correlated with overall survival (OS).
This research shows that senescence (biological aging) can occur in CAR-T cells, reducing their ability to kill cancer cells.
When Tim started to feel ill, the exact cause was unknown for a long time. It wasn’t until he presented with enlarged lymph nodes that he was referred to an oncologist who diagnosed him with CLL
